Oculis Holding (OCS)

• Market cap: $711M
• 1 day: -0.18%
• 5 days: -0.47%
• 1 month: 10.34%
• 3 months: 39.93%
• 6 months: 43.12%
• Year to date: 53.48%
• 1 year: 54.18%
• 5 years: 55.74%
• 10 years: 55.74%

About: Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Employees: 36

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

0.76% less ownership

Funds ownership: 7.98% [Q2] → 7.22% (-0.76%) [Q3]

7% less capital invested

Capital invested by funds: $39.8M [Q2] → $36.9M (-$2.82M) [Q3]

9% less funds holding

Funds holding: 11 [Q2] → 10 (-1) [Q3]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $30 77% upside
• Avg. target: $30 77% upside
• High target: $30 77% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Yi Chen 40% 1-year accuracy 62 / 155 met price target

77% upside $30

Buy Reiterated

11 Nov 2024